Minneapolis Heart Institute Foundation

Electrophysiology Research / Joseph F. Novogratz Family Heart Rhythm Center

November 2025 Bi-Annual Update

Center Highlights

Advance AF: The ADVANCE AF study, led by Dr. Daniel Melby, is evaluating Ripple Frequency mapping to identify and ablate atrial fibrillation (AF) drivers outside the left atrium in patients with persistent AF. This is our first study with international sites, with a target goal of 110 patients.

Study Spotlight: AIM HIGHer

Description

The study will assess the efficacy and safety of Cardiac Contractility Modulation therapy over an estimated duration of 5-6 years from first enrollment to study closure. The key inclusion criteria for this study are patients with symptomatic heart failure with a left ventricular ejection fraction ≥40 and ≤70%.

Contact

Efrah Hussein

Efrah.hussein@allina.com

Principal Investigator

Dr. Mike Samara

Enrolling Clinical Studies

Study

Study Description

PI and Enrolling Sites

ADVANCE AF

Investigator Initiated

Evaluate the effectiveness of ablation of novel Ripple Frequency Map identified atrial fibrillation drivers for treating persistent AF

Dr. Dan Melby

ANW

SURVEILLANCE

Medtronic

Provide continuing evaluation of multiple market-released pacing and ICD leads.

Dr. JoEllyn Moore

ANW and United

OMNY-AF

Impulse Dynamics, Inc.

Assess the safety and effectiveness of the OMNYPULSE PFA Platform for PVI in the treatment of subjects with symptomatic PAF.

Dr. Dan Melby

ANW

AIM HIGHer

Impulse Dynamics, Inc.

Evaluate the efficacy and safety of Cardiac Contractility Modulation therapy in patients with symptomatic HF with LVEF 40-60%.

Dr. Mike Samara

ANW

Pipeline Studies

BackBeat

Orchestra BioMed, Inc.

Evaluate the safety and effectiveness of a novel atrioventricular interval modulation algorithm in reducing blood pressure for patients with a dual-chamber pacemaker and uncontrolled hypertension despite antihypertensive medications.

Dr. Michael Peterson

United and ANW

Horizon 360

Medtronic

Demonstrate the safety and effectiveness of the Sphere-360TM Catheter and Affera TM Mapping and Ablation System for the treatment of recurrent, symptomatic PAF.

Dr. Jay Sengupta

ANW

Sphere PER-AF PAS Medtronic

Evaluate the long-term effectiveness and safety of the Sphere-9 Catheter and Affera Ablation System in a post-approval setting for the treatment of drug refractory, recurrent, symptomatic, persistent AF.

Dr. Edwin Zishiri

ANW

REACT-AF

Johns Hopkins University

Trial comparing continuous DOAC use versus time-delimited DOAC guided by an AF-sensing Smart Watch in participants with a history of paroxysmal or persistent AF and low-to-moderate stroke risk.

Dr. John Zakaib

ANW

Abbreviations: AHMHI = Abbott Hospital Minneapolis Heart Institute; ANW = Abbott Northwestern Hospital; CRT = cardiac resynchronization therapy; DOAC = direct oral anticoagulation; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardiac defibrillator; LBBAP = left bundle branch area pacing; LOT-CRT = Left bundle branch-optimized cardiac resynchronization therapy; LVEF = left ventricular ejection fraction; PAF = persistent atrial fibrillation; PVI = pulmonary vein isolation

For more information, please contact Julianne Feola at Julianne.Feola@allina.com

Interested in clinical trials from our other areas of cardiovascular research? Visit mplsheart.org/archive for any recent emails you may have missed.